MAJOR CANDIDATE
Legal data
Possible Advantages
- Doesn’t cause severe side effects.
- Could potentially be targeted to several types of cancer.
- It can potentially become a platform for the creation of new (more effective) virus strains.
Disadvantages
- Patent of 2017.
- Possibly should be used with other recognized treatments.
- Partial lysis of cancer cells, i.e., does not lead to complete healing. It is only prolong the patient’s life.
- What is — The Coxsackie Group B3 Virus Strain CVB3 PD-0
- The Fundamental Indication — Colorectal cancer
- Additional indications — Pancreatic cancer, Lung cancer
- Inventors — Henry Fechner, DVM Ahmet Hazini Vanessa Brueckner
- Patent owner — Technical University of Berlin
- Patent number — US 10,639,337
- Primary financing — Innovative Medicines Initiative 2 (IMI2-JU) under grant agreement №115797 INNODIA
- Technology copyright holder — NIVIRON INC based on an option contract giving exclusive rights to obtain rights to the technology
We cannot provide technology data without you signing the CDA. Please fill out the form to access information.